title: Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.
authors.forename: Ulas Darda
authors.initials: UD
authors.lastname: Bayraktar
authors.forename: Gelenis Calzadilla
authors.initials: GC
authors.lastname: Domingo
authors.forename: Jessica
authors.initials: J
authors.lastname: Schmit
authors.forename: Denise
authors.initials: D
authors.lastname: Pereira
mesh_terms: D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D055815:Young Adult
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D001374:Azacitidine